This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

$5 Stocks That Analysts Expect to Double

2. Cytokinetics (CYTK - Get Report) said on July 26 that it has been awarded a $2.9 million grant from the National Institute of Neurological Disorders and Stroke for preclinical and clinical development of CK-2017357, the company's treatment for myasthenia gravis, or muscle weakness and fatigue.

Share Price: $2.75 (July 30 close)

Average Price Target: $11.50, based on three analyst price targets of $7, $16.50 and $11 dating to May 11. From the current share price, the average price target from analysts signifies a 308% jump.

2010 Performance: -5.5%

Analysts' View: Five of the six analysts following Cytokinetics rate the stock a "buy," including JMP Securities and Canaccord Genuity. In a July 29 research note, Wedbush analyst Gregory Wade maintained his "outperform" rating on the stock and said he arrives at his $16.50 price target by adding $3.50 per share assigned to Cytokinetics' lead drug candidate, omecamtiv mecarbil, to his estimate of the company's anticipated appreciation of $13 per share for the potential of the company's skeletal muscle program.
4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIOD $0.41 -0.69%
CYTK $8.14 -1.50%
GSI $1.37 -3.50%
MNOV $6.89 -1.30%
OREX $0.45 -4.20%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs